Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 6412562

Next Previous
Drug Profile

PF 6412562

Alternative Names: PF-06412562; PF-6412562

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 21 Apr 2019 Milton Hershey Medical Center in collaboration with Pfizer completes enrolment in its phase I trial for Parkinson disease (In children, In adults, In the elderly) in USA (NCT03665454)
  • 11 Sep 2018 Pfizer initiates enrolment in a phase I trial for Parkinson's disease (In children, In adults, In the elderly) in USA (NCT03665454)
  • 06 Jul 2018 Pfizer initiates enrolment in a phase I trial (In volunteers) in USA (NCT03686501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top